An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Vivani Medical says it plans to start a human trial in August for a tiny implant that would slowly release semaglutide, the same drug in Ozempic and Wegovy. The company also announced a deal with Novo Nordisk to evaluate the implant, which suggests the big diabetes/weight-loss drugmaker is at least interested in looking into the idea. That’s the news in plain terms: a small medical-device company is moving toward testing a long-lasting way to deliver a well-known drug, and a major drugmaker is taking a formal look. Semaglutide is the active ingredient in popular medicines for diabetes and weight loss. In everyday language, it copies a natural hormone your gut makes after you eat. That hormone tells your brain you’re full and slows how fast your stomach empties, which helps reduce appetite and blood sugar spikes. Right now semaglutide is usually given as a weekly injection or as a daily pill; an implant aims to make delivery continuous over a long stretch so people wouldn’t need regular shots or pills. What the announcement actually says is about plans and partnerships, not finished proof. Vivani plans a human trial in August, which means they will test safety and how the implant behaves in people — likely a small, early-stage study. The deal with Novo Nordisk is for evaluation, meaning Novo Nordisk will look at the implant’s design or data; it does not mean approval, endorsement, or that Novo Nordisk will sell it. We don’t yet have results showing how well the implant works or whether it matches the effects of injections or pills. Until the human trial reports data, we don’t know the size of any benefit or how it compares to current treatments. This matters because a well-working implant could change convenience and consistency of treatment. For people who dislike injections, have trouble remembering weekly doses, or need steady drug levels, an implant could make life easier. It could also affect healthcare costs and who gets access, depending on pricing and insurance coverage. For Novo Nordisk, evaluating alternative delivery methods makes sense as demand for semaglutide-based treatments grows and competitors explore different ways to use the same drug. There are important caveats. Early trials focus on safety and basic behavior, not long-term effects or real-world effectiveness. Implants carry their own risks: infection, device failure, or complications when removing or replacing them. Regulatory approval can take a long time, and an evaluation deal is not the same as a partnership to market or a guarantee of success. People should not assume an implant will be available soon or is better than current options until larger trials and regulatory reviews are completed. Bottom line: A company is gearing up to test a semaglutide-releasing implant in people, and Novo Nordisk will evaluate it — promising for convenience but still at an early, uncertain stage.
Source: foreignpolicyjournal.com